CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Bought by Cetera Investment Advisers (2024)

Cetera Investment Advisers lifted its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 451.3% in the first quarter, Holdings Channel reports. The institutional investor owned 34,100 shares of the company’s stock after buying an additional 27,915 shares during the quarter. Cetera Investment Advisers’ holdings in CRISPR Therapeutics were worth $2,324,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Capital International Investors boosted its stake in CRISPR Therapeutics by 27.8% during the 1st quarter. Capital International Investors now owns 7,837,074 shares of the company’s stock valued at $534,175,000 after acquiring an additional 1,702,624 shares during the last quarter. Vanguard Group Inc. grew its position in shares of CRISPR Therapeutics by 2.9% in the 1st quarter. Vanguard Group Inc. now owns 1,636,799 shares of the company’s stock worth $111,564,000 after acquiring an additional 46,148 shares in the last quarter. SR One Capital Management LP bought a new stake in shares of CRISPR Therapeutics in the 1st quarter valued at approximately $71,496,000. Charles Schwab Investment Management Inc. raised its position in shares of CRISPR Therapeutics by 2.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 653,023 shares of the company’s stock valued at $40,879,000 after acquiring an additional 15,085 shares in the last quarter. Finally, Norges Bank bought a new position in CRISPR Therapeutics during the fourth quarter worth $38,661,000. Institutional investors own 69.20% of the company’s stock.

Insider Transactions at CRISPR Therapeutics

In related news, COO Julianne Bruno sold 3,366 shares of the firm’s stock in a transaction dated Friday, June 21st. The stock was sold at an average price of $56.09, for a total transaction of $188,798.94. Following the completion of the transaction, the chief operating officer now owns 6,745 shares of the company’s stock, valued at $378,327.05. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 4.10% of the company’s stock.

CRISPR Therapeutics Trading Down 1.8 %

Shares of NASDAQ:CRSP opened at $47.01 on Monday. The company has a 50 day moving average of $56.58 and a 200-day moving average of $62.73. The firm has a market cap of $3.99 billion, a P/E ratio of -17.28 and a beta of 1.70. CRISPR Therapeutics AG has a twelve month low of $37.55 and a twelve month high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) last announced its earnings results on Monday, August 5th. The company reported ($1.49) EPS for the quarter, missing the consensus estimate of ($1.43) by ($0.06). The company had revenue of $0.52 million during the quarter, compared to analysts’ expectations of $12.31 million. CRISPR Therapeutics’s quarterly revenue was down 99.3% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.98) earnings per share. Equities research analysts forecast that CRISPR Therapeutics AG will post -5.52 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have weighed in on CRSP shares. Royal Bank of Canada lowered their target price on shares of CRISPR Therapeutics from $66.00 to $60.00 and set a “sector perform” rating for the company in a research note on Tuesday, August 6th. Guggenheim reiterated a “neutral” rating on shares of CRISPR Therapeutics in a research note on Friday, June 28th. JMP Securities reissued a “market outperform” rating and issued a $86.00 target price on shares of CRISPR Therapeutics in a report on Thursday, May 9th. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of CRISPR Therapeutics in a report on Thursday. Finally, Robert W. Baird raised their price target on CRISPR Therapeutics from $46.00 to $52.00 and gave the stock a “neutral” rating in a report on Thursday, May 9th. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat, CRISPR Therapeutics has an average rating of “Hold” and an average target price of $74.00.

Read Our Latest Stock Report on CRSP

About CRISPR Therapeutics

(Free Report)

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

Further Reading

• Five stocks we like better than CRISPR Therapeutics
• What is the FTSE 100 index?
• Why Wall Street Analysts Raised Price Targets for Suncor Stock
• What Are Growth Stocks and Investing in Them
• Is Super Micro Computer a Buy After Shares Sink 20% on Earnings?
• What is Put Option Volume?
• Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid?

Want to see what other hedge funds are holding CRSP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report).

Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.